Prakt. lékáren. 2021; 17(2): 74-80 | DOI: 10.36290/lek.2021.015

Novel drugs in pharmacotherapy of obesity

Jan Miroslav Hartinger

Oddělení klinické farmakologie a farmacie, Farmakologický ústav, 1. lékařská fakulta Univerzity Karlovy a Všeobecná fakultní nemocnice v Praze

Obesity pharmacotherapy helps many patients to achieve significant and sustainable body weight reduction and improvement in comorbidities and overall prognosis. Four drugs to treat obesity are currently available in the Czech Republic: phentermine, orlistat, liraglutide and bupropion/naltrexone. Recently approved drugs (liraglutide and bupropion/naltrexone) are discussed in detail. Drugs recently withdrawn (lorcaserin and rimonabant) and most promising drugs in clinical studies (tesofensin and bimagrumab) are mentioned in brief. When tailoring the therapy for obese patient, drugs to treat comorbidities (e. g. depression, diabetes) should be carefully chosen so that they do not increase the body weight as a side effect. On the other hand pharmacotherapeutic modality for obesity treatment should be appropriately chosen so that it does not worsen any other disease of the patient as a side effect.

Keywords: liraglutide, semaglutide, bupropion/naltrexone, tesofensine, bimagrumab.

Published: August 5, 2021  Show citation